Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Relmada Therapeutics (RLMD) Profit After Tax (2016 - 2026)

Relmada Therapeutics has reported Profit After Tax over the past 3 years, most recently at -$3124.0 for Q1 2014.

  • Quarterly Profit After Tax rose 24.65% to -$3124.0 in Q1 2014 from the year-ago period, while the trailing twelve-month figure was -$36983.0 through Feb 2014, down 52.34% year-over-year, with the annual reading at -$57.4 million for FY2025, 28.25% up from the prior year.
  • Profit After Tax was -$3124.0 for Q1 2014 at Relmada Therapeutics, up from -$14374.0 in the prior quarter.
  • Over five years, Profit After Tax peaked at -$2481.0 in Q2 2012 and troughed at -$19485.0 in Q2 2013.
  • The 3-year median for Profit After Tax is -$8629.0 (2012), against an average of -$8751.3.
  • Year-over-year, Profit After Tax crashed 685.37% in 2013 and then rose 24.65% in 2014.
  • A 3-year view of Profit After Tax shows it stood at -$9020.0 in 2012, then plummeted by 59.36% to -$14374.0 in 2013, then soared by 78.27% to -$3124.0 in 2014.
  • Per Business Quant, the three most recent readings for RLMD's Profit After Tax are -$3124.0 (Q1 2014), -$14374.0 (Q4 2013), and -$19485.0 (Q2 2013).